Perrigo has completed the acquisition of Rosemont Pharmaceuticals, based in Leeds, UK, for approximately $283 million in cash. Rosemont is a specialty and generic pharmaceutical company focused on the manufacturing and marketing of oral liquid formulations, with a portfolio of more than 90 products. Rosemont’s sales were approximately $60 million in 2012.   Perrigo chairman, president and chief executive officer Joseph C. Papa said, “We continue to focus on expanding our internationa...